【摘要】 目的：分析重组组织型纤溶酶原激活剂（rt-PA）静脉溶栓结合丁苯酞治疗急性脑梗死的临床效果。方法：回顾性分析2020年1月—2022年1月北京市普仁医院收治的90例急性脑梗死患者的临床资料，根据不同的治疗方法将患者分为研究组和对照组，各45例。两组患者均进行常规治疗，对照组患者进行rt-PA静脉溶栓治疗，研究组在对照组的基础上联合丁苯酞治疗。对比两组临床治疗效果及不良反应，比较治疗前后患者的血清炎症因子水平、神经损伤标志物及日常生活自理能力。结果：研究组总有效率为95.56%，高于对照组的80.00%，差异有统计学意义（P<0.05）。两组头晕、皮疹、牙龈出血、恶心呕吐等不良情况发生率对比，差异无统计学意义（P>0.05）。两组治疗前各项血清炎症因子对比，差异无统计学意义（P>0.05）；治疗后，研究组肿瘤坏死因子-α(TNF-α)、C反应蛋白（CRP）、白细胞介素-2(IL-2)、白细胞介素-6(IL-6)均低于对照组，差异有统计学意义（P<0.05）。两组治疗前神经元特异性烯醇化酶（NSE）及Barthel指数评分（BI评分）对比，差异无统计学意义（P>0.05）；治疗后，研究组NSE水平明显低于对照组，BI评分高于对照组，差异有统计学意义（P<0.05）。结论：在急性脑梗死的临床治疗中，使用rt-PA静脉溶栓结合丁苯酞的治疗效果好，可有效抑制患者炎症反应，减轻神经损伤，改善生活质量，且安全性好。更多还原

【Abstract】 Objective: To analyze the clinical efficacy of recombinant tissue plasmin activator(rt-PA) intravenous thrombolysis combined with Butylphthalide in the treatment of acute cerebral infarction. Method: The clinical data of 90 patients with acute cerebral infarction admitted to Beijing Puren Hospital from January 2020 to January 2022 were analyzed retrospectively. Based on different treatment methods, the patients were divided into study group and control group, with 45 patients in each group. The patients in both groups received routine treatment. The patients in the control group received intravenous thrombolysis with rt-PA. The patients in the study group were treated with Butylphthalide on the basis of the control group. The clinical treatment efficacy and adverse reactions between two groups were compared, the levels of serum inflammatory factors, nerve injury markers, and daily living ability of patients before and after treatment were compared. Result: Compared with the total effective rate of 80.00% in the control group, the study group has a higher total effective rate of 95.56%, the difference was statistically significant(P<0.05). There were no statistically significant differences in the incidences of adverse events such as dizziness, rash, gum bleeding, nausea and vomiting between the two groups(P>0.05).There were no differences in the comparison of various serum inflammatory factors between the two groups before treatment(P>0.05); after treatment, the tumor necrosis factor-α(TNF-α), C-reactive protein(CRP), interleukin-2(IL-2), interleukin-6(IL-6) in the study group were lower than those in the control group, the differences were statistically significant(P<0.05). There were no statistically significant differences in neuron-specific enolase(NSE) and Barthel index score(BI score) between the two groups before treatment(P>0.05); after treatment, the NSE level of the study group was significantly lower than that in the control group, and the BI score was higher than that in the control group, the differences were statistically significant(P<0.05). Conclusion: In the clinical treatment of acute cerebral infarction,rt-PA intravenous thrombolysis combined with Butylphthalide has a good therapeutic effect, which can effectively inhibit the inflammatory response of patients, reduce nerve damage, improve quality of life, and it is safe.更多还原